Elimination profile of triamcinolone hexacetonide and its metabolites in human urine and plasma after a single intra-articular administration

Triamcinolone hexacetonide (THA) is a synthetic glucocorticoid (GC) used by intra-articular (IA) administration. GCs are prohibited in sports competitions by systemic routes, and they are allowed by other routes considered of local action (IA administration, among others). The aim of the present wor...

Descripción completa

Detalles Bibliográficos
Autores: Coll Camenforte, Sergi, 1991-, Matabosch Geronès, Xavier, Llorente Onaindia, Jone, Carbó Banús, Marcel·lí, Pérez Mañá, Clara, Monfort Mercader, Núria, 1983-, Monfort, Jordi, Ventura Alemany, Rosa
Tipo de recurso: artículo
Estado:Versión aceptada para publicación
Fecha de publicación:2019
País:España
Institución:Universitat Pompeu Fabra
Repositorio:Repositorio Digital de la UPF
OAI Identifier:oai:repositori.upf.edu:10230/43686
Acceso en línea:http://hdl.handle.net/10230/43686
http://doi.org/10.1002/dta.2614
Access Level:acceso abierto
Palabra clave:Adverse analytical finding
Doping
Glucocorticoids
Triamcinolone hexacetonide
id ES_fccf3010bc3ac89ef0b4ac2a96c844be
oai_identifier_str oai:repositori.upf.edu:10230/43686
network_acronym_str ES
network_name_str España
repository_id_str
spelling Elimination profile of triamcinolone hexacetonide and its metabolites in human urine and plasma after a single intra-articular administrationColl Camenforte, Sergi, 1991-Matabosch Geronès, XavierLlorente Onaindia, JoneCarbó Banús, Marcel·líPérez Mañá, ClaraMonfort Mercader, Núria, 1983-Monfort, JordiVentura Alemany, RosaAdverse analytical findingDopingGlucocorticoidsTriamcinolone hexacetonideTriamcinolone hexacetonide (THA) is a synthetic glucocorticoid (GC) used by intra-articular (IA) administration. GCs are prohibited in sports competitions by systemic routes, and they are allowed by other routes considered of local action (IA administration, among others). The aim of the present work was to study the metabolic profile of THA in urine and plasma following IA administration. Eight patients (4 males and 4 females) with knee osteoarthritis received an IA dose of THA (40 mg) in the knee joint. Spot urine and plasma samples were collected before injection and at different time periods up to day 23 and 10 post-administration, respectively. The samples were analysed by liquid chromatography-tandem mass spectrometry. Neither THA nor specific THA metabolites were detected in urine. Triamcinolone acetonide (TA) and 6β-hydroxy-triamcinolone acetonide were the main urinary metabolites. Maximum concentrations wereobtained between 24 and 48 h after administration. Using the reporting level of 30 ng/mL to distinguish allowed from forbidden administrations of GCs, a large number of false adverse analytical findings would be reported up to day 4. On the other hand, TA was detected in all plasma samples collected up to day 10 after administration. THA was also detected in plasma but at lower concentrations. The detection of plasma THA would be an unequivocal proof to demonstrate IA use of THA. A reversible decrease was observed in plasma concentrations of cortisol in some of the patients, indicating a systemic effect of the drug.Wiley20202019info:eu-repo/semantics/articleinfo:eu-repo/semantics/acceptedVersionapplication/pdfapplication/pdfhttp://hdl.handle.net/10230/43686http://doi.org/10.1002/dta.2614reponame:Repositorio Digital de la UPFinstname:Universitat Pompeu FabraInglésDrug Testing and Analysis. 2019 Nov;11(11-12):1589-600This is the peer reviewed version of the following article: Coll S, Matabosch X, Llorente-Onaindia J, Carbó ML, Pérez-Mañá C, Monfort N. et al. Elimination profile of triamcinolone hexacetonide and its metabolites in human urine and plasma after a single intra-articular administration. Drug Test Anal. 2019 Nov; 11 (11-12):1589-1600, which has been published in final form at http://dx.doi.org/10.1002/dta.2614. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.info:eu-repo/semantics/openAccessoai:repositori.upf.edu:10230/436862026-06-12T07:21:37Z
dc.title.none.fl_str_mv Elimination profile of triamcinolone hexacetonide and its metabolites in human urine and plasma after a single intra-articular administration
title Elimination profile of triamcinolone hexacetonide and its metabolites in human urine and plasma after a single intra-articular administration
spellingShingle Elimination profile of triamcinolone hexacetonide and its metabolites in human urine and plasma after a single intra-articular administration
Coll Camenforte, Sergi, 1991-
Adverse analytical finding
Doping
Glucocorticoids
Triamcinolone hexacetonide
title_short Elimination profile of triamcinolone hexacetonide and its metabolites in human urine and plasma after a single intra-articular administration
title_full Elimination profile of triamcinolone hexacetonide and its metabolites in human urine and plasma after a single intra-articular administration
title_fullStr Elimination profile of triamcinolone hexacetonide and its metabolites in human urine and plasma after a single intra-articular administration
title_full_unstemmed Elimination profile of triamcinolone hexacetonide and its metabolites in human urine and plasma after a single intra-articular administration
title_sort Elimination profile of triamcinolone hexacetonide and its metabolites in human urine and plasma after a single intra-articular administration
dc.creator.none.fl_str_mv Coll Camenforte, Sergi, 1991-
Matabosch Geronès, Xavier
Llorente Onaindia, Jone
Carbó Banús, Marcel·lí
Pérez Mañá, Clara
Monfort Mercader, Núria, 1983-
Monfort, Jordi
Ventura Alemany, Rosa
author Coll Camenforte, Sergi, 1991-
author_facet Coll Camenforte, Sergi, 1991-
Matabosch Geronès, Xavier
Llorente Onaindia, Jone
Carbó Banús, Marcel·lí
Pérez Mañá, Clara
Monfort Mercader, Núria, 1983-
Monfort, Jordi
Ventura Alemany, Rosa
author_role author
author2 Matabosch Geronès, Xavier
Llorente Onaindia, Jone
Carbó Banús, Marcel·lí
Pérez Mañá, Clara
Monfort Mercader, Núria, 1983-
Monfort, Jordi
Ventura Alemany, Rosa
author2_role author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Adverse analytical finding
Doping
Glucocorticoids
Triamcinolone hexacetonide
topic Adverse analytical finding
Doping
Glucocorticoids
Triamcinolone hexacetonide
description Triamcinolone hexacetonide (THA) is a synthetic glucocorticoid (GC) used by intra-articular (IA) administration. GCs are prohibited in sports competitions by systemic routes, and they are allowed by other routes considered of local action (IA administration, among others). The aim of the present work was to study the metabolic profile of THA in urine and plasma following IA administration. Eight patients (4 males and 4 females) with knee osteoarthritis received an IA dose of THA (40 mg) in the knee joint. Spot urine and plasma samples were collected before injection and at different time periods up to day 23 and 10 post-administration, respectively. The samples were analysed by liquid chromatography-tandem mass spectrometry. Neither THA nor specific THA metabolites were detected in urine. Triamcinolone acetonide (TA) and 6β-hydroxy-triamcinolone acetonide were the main urinary metabolites. Maximum concentrations wereobtained between 24 and 48 h after administration. Using the reporting level of 30 ng/mL to distinguish allowed from forbidden administrations of GCs, a large number of false adverse analytical findings would be reported up to day 4. On the other hand, TA was detected in all plasma samples collected up to day 10 after administration. THA was also detected in plasma but at lower concentrations. The detection of plasma THA would be an unequivocal proof to demonstrate IA use of THA. A reversible decrease was observed in plasma concentrations of cortisol in some of the patients, indicating a systemic effect of the drug.
publishDate 2019
dc.date.none.fl_str_mv 2019
2020
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/acceptedVersion
format article
status_str acceptedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10230/43686
http://doi.org/10.1002/dta.2614
url http://hdl.handle.net/10230/43686
http://doi.org/10.1002/dta.2614
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Drug Testing and Analysis. 2019 Nov;11(11-12):1589-600
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Wiley
publisher.none.fl_str_mv Wiley
dc.source.none.fl_str_mv reponame:Repositorio Digital de la UPF
instname:Universitat Pompeu Fabra
instname_str Universitat Pompeu Fabra
reponame_str Repositorio Digital de la UPF
collection Repositorio Digital de la UPF
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869425483303616512
score 15.812455

Similares en LA Referencia